NCIt definition : A humanized monoclonal antibody against matrix metalloproteinase 9 (MMP-9), with potential
antineoplastic activity. Upon administration, andecaliximab binds to MMP-9 and inhibits
its enzymatic activity. This results in an inhibition of extracellular matrix protein
degradation and, potentially, the inhibition of angiogenesis, tumor growth, invasion,
and metastasis. MMP-9, a protein belonging to the MMP family, plays a key role in
the degradation of collagens and proteoglycans; increased activity of MMP-9 has been
associated with increased invasion and metastasis of cancer.;
UNII : 571045EIM4;
CAS number : 1518996-49-0; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1518996-49-0
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;